Combining Loncastuximab Tesirine and Epcoritamab in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)

This is a phase II study designed to evaluate the toxicity and efficacy of the combination of loncastuximab tesirine and epcoritamab in patients with relapsed/refractory aggressive B-cell lymphoma. Chimeric antigen receptor (CAR)-T cell naive patients who have failed first-line therapy and patients who have received CAR-T cells as second-line therapy and experienced CAR-T failure will be eligible for inclusion.

Trial Details

NCT ID
NCT07197307
Phase
PHASE2
Sponsor
Universität Münster
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Loncastuximab Tesirine and Epcoritamab
Locations (sample)
  • Aachen, Germany|50.77664,6.08342
  • Augsburg, Germany|48.37154,10.89851
  • Berlin, Germany|52.52437,13.41053
  • Berlin, Germany|52.52437,13.41053
  • Berlin, Germany|52.52437,13.41053

Key Eligibility Criteria

  • Subjects with histologically confirmed relapsed/refractory DLBCL based on pathology report (WHO 2022 criteria)
  • DLBCL (de novo or transformed)
  • High-grade B-cell lymphoma with MYC and BCL2 rearrangements
  • High-grade B-cell lymphoma, not otherwise specified (NOS)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →